MARKET NEWS

Ubiquigent Launches a New Service to Facilitate Target Validation of DUB Enzymes & Determine Compound-DUB Target Engagement & Selectivity of Novel Compounds in Cells
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134
Vetter Aligns its Development Service Laboratory Portfolio 
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept 
Cabaletta Bio Receives Orphan Drug Designation for DSG3-CAART 
Akcea & Ionis Report Positive Topline Phase 2 Study Results

  FEATURED EDITORIAL

  COMPANY PROFILE

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement

Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement

Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….

Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases

Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases

Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….

BioPharmX & Timber Pharmaceuticals Announce Merger Agreement

BioPharmX & Timber Pharmaceuticals Announce Merger Agreement

BioPharmX Corporation and Timber Pharmaceuticals LLC recently announced they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 12 – Injection Devices
February 19 – Formulation Development